Welcome to our dedicated page for Neuropace news (Ticker: NPCE), a resource for investors and traders seeking the latest updates and insights on Neuropace stock.
NeuroPace Inc (NPCE) is a pioneering medical technology company developing brain-responsive neuromodulation systems for epilepsy treatment. This page serves as the definitive source for official company announcements, financial updates, and clinical progress reports.
Access timely updates on NPCE's innovative RNS System, including FDA regulatory milestones, partnership developments with leading epilepsy centers, and peer-reviewed clinical study results. Investors will find earnings reports and strategic initiatives, while healthcare professionals can track real-world treatment outcomes and technological refinements.
Our curated news collection features:
- Quarterly financial performance updates
- RNS System enhancement announcements
- Clinical trial data publications
- Regulatory clearance milestones
- Research collaborations with medical institutions
Bookmark this page for structured access to NPCE's evolving role in neurotechnology and epilepsy care innovation.
NeuroPace (Nasdaq: NPCE), a medical device company focused on epilepsy treatment, has announced its participation in two major healthcare conferences this September. The company will:
- Attend the Wells Fargo 2024 Healthcare Conference on September 4 in Boston, hosting one-on-one investor meetings
- Present at the Morgan Stanley 22nd Annual Global Healthcare Conference from September 4-6 in New York
At the Morgan Stanley conference, CEO Joel Becker and CFO Rebecca Kuhn will participate in a fireside chat on September 6 at 8:30am ET, which will be webcast live. They will also host one-on-one investor meetings. A replay of the fireside chat will be available on NeuroPace's Investor website.
NeuroPace (NPCE) reported strong Q2 2024 financial results, with revenue growing 17% to $19.3 million compared to Q2 2023. The company increased its full-year 2024 revenue guidance to $76-$78 million. Key highlights include:
- Expanded gross margin to 73.4% from 72.5% in Q2 2023
- Decreased cash burn to $4.0 million from $4.4 million in Q2 2023
- Completed initial hiring of expanded commercial organization
- Continued progress in executing growth strategy, including expanding commercial organization and increasing active prescribing epileptologists
NeuroPace remains focused on generating broader adoption of RNS therapy and closing the treatment gap for drug-resistant epilepsy patients.
NeuroPace (Nasdaq: NPCE), a medical device company specializing in epilepsy treatment, has announced its plans to release second quarter 2024 financial results on August 13, 2024, after market close. The company will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day to discuss the results.
Investors can access the live webcast at https://viavid.webcasts.com/starthere.jsp?ei=1677457&tp_key=a97b4f856d or join via telephone by dialing +1-877-407-3982 (Conference ID: 13747326). The webcast will be archived on NeuroPace's investor relations website for at least 90 days after the event.
NeuroPace (Nasdaq: NPCE), a medical device company specializing in epilepsy treatment, announced its participation in two healthcare conferences in May 2024. The company will join the Wells Fargo 2024 West Coast MedTech Tour on May 28 at 2:30pm PT in Menlo Park, CA, featuring a fireside chat with investors.
Additionally, NeuroPace will present at the Leerink Partners Healthcare Crossroads Conference from May 28-30 in Austin, TX. CEO Joel Becker will deliver a corporate presentation on May 30 at 8:00am CT, and the company will engage in one-on-one meetings with investors. The presentation will be available via live webcast and replay on NeuroPace’s Investor website.
NeuroPace, Inc. (NPCE) reported total revenue of $18.1 million in Q1 2024, a 25% increase from Q1 2023. The company extended its term loan maturity, maintained full-year revenue guidance of $73 to $77 million, and achieved growth in RNS System and DIXI Medical sales. Operating expenses were managed effectively, resulting in decreased losses compared to the prior year. The company remains focused on expanding market reach and increasing access to RNS therapy for epilepsy patients.
FAQ
What is the current stock price of Neuropace (NPCE)?
What is the market cap of Neuropace (NPCE)?
